WO2007097325A1 - リン酸オセルタミビル含有医薬組成物 - Google Patents
リン酸オセルタミビル含有医薬組成物 Download PDFInfo
- Publication number
- WO2007097325A1 WO2007097325A1 PCT/JP2007/053081 JP2007053081W WO2007097325A1 WO 2007097325 A1 WO2007097325 A1 WO 2007097325A1 JP 2007053081 W JP2007053081 W JP 2007053081W WO 2007097325 A1 WO2007097325 A1 WO 2007097325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- sugar
- composition according
- weight
- oseltamivir phosphate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Definitions
- the present invention relates to a pharmaceutical composition containing oseltamivir phosphate, in particular, a pharmaceutical composition containing oseltamivir phosphate excellent in long-term storage stability, and a solid preparation containing oseltamivir phosphate.
- Oseltamivir Phosphate (Compound name: (1) One (3R, 4R, 5S) 4 Acetamido-5 Amino 3— (1-Ethylpropoxy) cyclohexe 1—Yen 1 1-Carbon Ethyl ester monophosphate, (English: (-) -ethyl (3R, 4R, 5S) -4-acetamido-5-amino-3- (l-ethyl propoxy) cyclohex— 1—ene— 1—carboxy It has a potent inhibitory activity against te monophospnate bacilli, nephronidase nephronidase (Patent Document 1), and is used as an active ingredient in Tamiflu (registered trademark), a preventive or therapeutic agent for influenza.
- Tamiflu registered trademark
- Oseltamivir phosphate has been widely formulated as a capsule, and in recent years, it has also been formulated as a dry syrup for the convenience of formulating especially for children.
- powders or granules containing fine granules for packaging (hereinafter referred to as granules, etc.) must be stored under specified conditions for the period until they are used up after opening.
- the granules, etc. have a higher degree of storage stability against light, moisture, temperature, etc. in the storage environment, in particular, suppression of coloring, suppression of consolidation and aggregation. There is a need to provide such granules.
- Patent Document 1 International Publication WO 1998Z007685 Pamphlet
- the present invention contains oseltamivir phosphate having improved storage stability, in particular storage stability against humidity, temperature, etc. in the storage environment, in particular, coloration suppression during storage.
- An object of the present invention is to provide a pharmaceutical composition.
- the inventors of the present invention have conducted extensive research to solve the above-mentioned problems, and have found an improved storage stability in a oseltamivir phosphate formulation containing a specific excipient. Completed the invention.
- a pharmaceutical composition comprising an excipient and oseltamivir phosphate, wherein the excipient is selected from erythritol, D-mannitol and sucrose.
- a pharmaceutical composition as defined herein which is a force that is a sugar or sugar alcohol, or a mixture of two or more.
- the pharmaceutical composition according to the present invention provides, for example, prevention or prevention of a disease state selected from influenza virus infection and bronchitis, pneumonia, systemic pain, and fever associated with the infection. Can be used for treatment.
- the pharmaceutical composition according to the present invention may contain optional components (for example, a water-soluble polymer, a high-intensity sweetener, an anti-caking agent, etc.).
- the water-soluble polymer that can be used in the present invention is preferably selected from, for example, povidone, methylcellulose, carmellose sodium (synonymous with carboxymethylcellulose sodium, hereinafter referred to as carmellose sodium) and Macrogol 6000. sell.
- the high-intensity sweetener that can be used in the present invention can be, for example, preferably selected from dipotassium glycyrrhizinate, stevia extract, acesulfame potassium and saccharin sodium.
- the anti-caking aggregation agent that can be used in the present invention is not particularly limited, and for example, light anhydrous caustic acid or corn starch is preferable, and light anhydrous caustic acid is preferable.
- the present invention is as described herein, wherein the dosage form is a granule or the like.
- a pharmaceutical composition defined as is provided.
- one or more pharmaceutical acceptable tolerances selected from sugars and sugar alcohols having an equilibrium water content of less than weight percent at 25 ° C and 70% relative humidity.
- Selected from influenza virus infection and bronchitis, pneumonia, systemic pain, and fever associated with the infection comprising administering to the subject a pharmaceutical composition comprising an excipient and an effective amount of oseltamivir phosphate
- a method for preventing or treating a disease state wherein the contents of glucose and mannose contained in the sugar and sugar alcohol are each 0.01% by weight or less.
- Oseltamivir phosphate used in the present invention can be synthesized by, for example, a method disclosed in International Publications W1998 / 007685, W1996 / 026933, and the like.
- Oseltamivir phosphate for example, is an influenza virus infection and a disease state selected from bronchitis, pneumonia, systemic pain, and fever associated with the infection, particularly preferably an influenza A or B virus infection Can be used for treatment or prevention of symptoms. Since oseltamivir phosphate has a bitter taste, it is preferable to take measures to alleviate it.
- the bitterness can be masked by filling capsules, but when taking it in a dissolved state such as a syrup taken by children, it is necessary to devise a formulation that suppresses the bitterness. Therefore, from the viewpoint of reducing the bitter taste of oseltamivir phosphate, the blending ratio of oseltamivir phosphate in the unit dosage form is preferably low. On the other hand, the smaller the total amount of the unit dosage form, the less the burden on the patient when taking the drug, and the active ingredient can be administered efficiently. From this viewpoint, it is preferable that the blending ratio of the active ingredient in the unit dosage form is high. In general, the active ingredient is considered to be more stable in the preparation as the blending ratio is higher.
- the blending ratio of oseltamivir phosphate in the preparation can be appropriately determined by those skilled in the art.
- the blending ratio in the preparation is preferably 1 to 10% by weight, more preferably 1 to 7%. % By weight, more preferably 3 to 5% by weight.
- the sugar and sugar alcohol (excipient) used in the pharmaceutical composition according to the present invention is 25 ° C.
- the equilibrium moisture content at 70% relative humidity is 1% by weight or less. That is, the equilibrium water content is determined by leaving the sample (sugar or sugar alcohol) in air kept at a constant temperature of 25 ° C and a relative humidity of 70% for a long time, so that the water content in the sample is constant. It can be determined by measuring when
- Preferred sugars and sugar alcohols are erythritol, D-mannitol and sucrose, and erythritol can be used particularly preferably.
- the sugar and sugar alcohol used in the pharmaceutical composition according to the present invention have the property that the amounts of glucose and mannose contained as impurities are each 0.01% by weight or less.
- the contents of glucose and mannose in the sugar and sugar alcohol can be measured by methods well known in the technical field of pharmaceutical preparations (for example, HPLC method).
- HPLC method HPLC method
- it is generally obtained by purifying the sugar or sugar alcohol produced by column separation and / or recrystallization.
- One or more water-soluble polymers used in the pharmaceutical composition according to the present invention are used by a method well known in the technical field of pharmaceutical preparations as necessary for the convenience of manufacturing the preparations. be able to.
- the water-soluble polymer that can be used in the present invention is not particularly limited, but specific examples include povidone, pullulan, hydroxypropyl cellulose, methinoresenorelose, hydroxypropino methenoresenololose, strength. Examples include Vietnameselose sodium, carmellose potassium, macrogonole 6000, gelatin and alpha-denaturated starch, preferably povidone, methylcellulose, carmellose sodium and macrogol 6000, particularly preferably povidone, methylcellulose and carmellose sodium. .
- the water-soluble polymer can be used as a binder in order to enhance the production suitability of the preparation particularly when it is produced by a wet granulation method.
- the water-soluble polymer powder is used as another preparation. It may be added to the solid material and mixed, followed by wet granulation, or a part or all of the water-soluble polymer may be dissolved in water and added during granulation.
- high-intensity sweeteners used in the pharmaceutical composition according to the present invention, the ability to use high-intensity sweeteners well known in the technical field of pharmaceutical preparations as necessary. S can.
- the high-intensity sweetener in the present invention means a sweetener having a sweetness higher than that of sucrose.
- Specific examples of high-intensity sweeteners contemplated for use in the present invention include saccharin sodium, stevia extract, glycyrrhizic acid, glycyrrhizic acid salts including dipotassium glycyrrhetic acid, thaumatin, sucralose, and acesulfol.
- the high-intensity sweetener can be used to mask the bitter taste of oseltamivir phosphate, particularly in a dosage form such as dry syrup.
- the high-intensity sweetener powder can be used in other preparations. Wet granulation may be performed after adding to and mixed with the solid material, or a part or all of the high-intensity sweetener may be dissolved in water and added during granulation.
- One or more anti-caking agents used in the pharmaceutical composition according to the present invention may be used in the technical field of pharmaceutical formulations as necessary to prevent the caking aggregation of the formulations in a storage environment. Can be used by a well-known technique.
- the anti-caking agent that can be used in the present invention is not particularly limited. Specific examples include hydrous silicon dioxide, light anhydrous caustic acid, crystalline cellulose, titanium oxide, corn starch, and low-substituted hydroxy. Propylcellulose, preferably light anhydrous caustic acid and corn starch, particularly preferably light anhydrous anhydrous.
- the anti-caking agent can be used, for example, by adding powder to the granulated product and mixing it.
- the sugars and sugar alcohols used as excipients in the present invention also serve as a bulking agent for the production of the preparation. Based on the above viewpoints, sugars and sugar alcohols
- the mixing ratio in the preparation can be appropriately determined by those skilled in the art.
- the content ratio of sugar and sugar alcohol in the pharmaceutical composition according to the present invention (when two or more sugars and sugar alcohols are included, the total amount thereof) is, for example, 75 to 98% by weight, preferably 80 to 92% by weight. %.
- the pharmaceutical composition according to the present invention may further contain optional components such as a water-soluble polymer, a high-intensity sweetener, and an anti-caking agent.
- the addition amount of the water-soluble polymer (the total amount when containing two or more water-soluble polymers) is not particularly limited, but is, for example, 0.5 to 20% by weight, preferably:! It can be added in the range of 10% by weight.
- the amount of the high-intensity sweetener added (the total amount when two or more high-intensity sweeteners are included) is not particularly limited, but is, for example, 0.0 :! to 5% by weight, preferably Can be added in the range of 0.05 to 2% by weight.
- the addition amount of the anti-caking agent (the total amount when two or more anti-caking agents are included) is not particularly limited, but is, for example, 0.0:! To 5% by weight, preferably Can be added in the range of 0.05 to 2% by weight.
- the pharmaceutical composition according to the present invention may further contain additional optional components.
- the additional optional components are not particularly limited as long as they are components usually used in pharmaceutical preparations. Specific examples thereof include a flavoring agent, a suspending agent, a thickening agent, a fluidizing agent, a disintegrating agent, a dispersing agent, and a fragrance.
- a flavoring agent e.g., peppermint, peppermint, a peppermint, a peppermint, a peppermint, pepper, a pepper, a pepper, a pepper, a sulfate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate, a fate,
- the pharmaceutical composition according to the present invention can be prepared by appropriately combining the above-described components with oseltamivir phosphate and the sugar or sugar alcohol.
- the form of the pharmaceutical composition in the present invention is not particularly limited, but is preferably an oral solid preparation such as a tablet, capsule, powder, granule, fine granule, or dry syrup, and particularly preferably powder or granule.
- the dry syrup means a solid preparation that becomes a syrup by adding water or the like when dissolved and dissolving or suspending.
- the powders, granules, and fine granules referred to in this specification comply with the standards described in the Japanese Pharmacopoeia. For example, a granule granulates a medicine No. 5 (1400 / im) sieve passes through the entire screen and remains in the No.
- the powder is a powdered pharmaceutical product that passes through the No. 18 (85 0 ⁇ m) sieve and the remaining amount on the No. 30 (500 ⁇ m) sieve is less than 5% of the total quantity. It is. Of the powders, those that pass through a No. 200 (75 xm) sieve and are not more than 10% of the total amount can be called fine granules.
- the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising oseltamivir phosphate and a sugar or sugar alcohol (excipient), preferably oseltamivir phosphate, sugar or sugar alcohol (excipient), and a high-intensity sweetener.
- a pharmaceutical composition comprising oseltamivir phosphate, sugar or sugar alcohol (excipient), a high-intensity sweetener, and a water-soluble polymer, most preferably oseltamivir phosphate.
- a sugar or sugar alcohol, a high-sweetness sweetener, a water-soluble polymer, and an anti-caking agent is preferably oseltamivir phosphate and a sugar or sugar alcohol (excipient), preferably oseltamivir phosphate, sugar or sugar alcohol (excipient), and a high-intensity sweetener.
- the compounding ratio in the most preferred pharmaceutical composition is:
- High intensity sweetener 0.01 to 5% by weight
- Anti-caking agent 0.01 to 5% by weight
- Anti-caking agent 0.05-2% by weight
- Anti-caking agent 0.05-0.1% by weight
- composition may contain optional ingredients as necessary.
- Equilibrium moisture content (25 ° C, relative humidity 70%) in sugar or sugar alcohol can be measured using a dynamic moisture adsorption isothermal device DVS-1 (Surface Measurement Systems). The measurement conditions are shown below.
- Relative humidity measurement step Up to 10%
- Hold time Weight change Moves to the next step with less than 0.02%, but is stable.
- Glucose and mannose contained as impurities in sugar and sugar alcohol were separated by ion chromatography and quantified by electrochemical detection. The measurement conditions are shown below.
- Electrochemical detector Electrochemical detector
- Mobile phase A Water; Mobile phase B: 10 mM sodium hydroxide aqueous solution; Mobile phase C: 200 mM sodium hydroxide aqueous solution Gradient: Set as shown in Table 1 below. The mobile phase composition is stated in volume%.
- aqueous solutions of D-glucose and D-mannose were prepared and used as standard solutions.
- the standard solution concentration corresponds to 0.001, 0.01, 0.05, and 0.1% when an unknown sample solution is prepared at 500 mg / lOmL.
- a calibration curve was prepared from the standard solution concentration and peak area by operating under the above-mentioned HPLC conditions. Separately, an unknown sample of 500 mg was accurately weighed and water was added to make exactly 1 mL, which was used as the sample solution.
- the D_darcose and D_mannose concentrations were quantified from the area values of the peaks corresponding to the elution positions of D—gnolecose and D—mannose, and the amounts of D_darcose and D—mannose in the sample were determined. Calculated.
- the color tone of the mixture was measured in the same manner, under the conditions of storage in a warm bath for 2 weeks, and ii) in a thermostatic bath set at 40 ° C 75% RH and stored for 1 month in an open state.
- the color difference AE * (CIE L * a * b *) before and after storage was measured.
- the color difference was measured based on the 0-45 ° post-spectral method according to JIS Z-8722, and a spectral color difference meter (SE-2 000) (manufactured by Nippon Denshoku Industries Co., Ltd.) was used for the measurement. .
- erythritol, D-sorbitol and D-mannitol were measured for their equilibrium water content, glucose content and mannose content, respectively, and were as follows:
- Erythritol had an equilibrium water content (25 ° C, relative humidity 70%) of 0.1%, a glucose content of 0.001%, and a mannose content of 0.001%.
- D-sorbitol has an equilibrium water content (25 ° C, relative humidity 70%) of 1.7%, glucose content of 0.006%, The content of N-nose was 0 ⁇ 032%.
- D-mannitol had an equilibrium water content (25 ° C, relative humidity 70%) of 0 ⁇ 0%, glucose content ND, and mannose content ND (ND: below detection limit).
- Wet granulation was performed by mixing 27 g of various sugar alcohols and 3 g of oseltamivir phosphate in a mortar and adding 1 mL of water thereto and kneading. Dry for 3 hours with a constant-temperature dryer set to 50 ° C, keep the water content in the formulation to 1% by weight or less, then store tightly at 60 ° C for 4 weeks, and measure the color change before and after storage with a color difference meter. did.
- a trial production was conducted on an lkg scale, and a study was conducted to granulate condyles with 1 to 10% of oseltamivir phosphate.
- the raw materials are weighed at the following blending ratio, put into a high-speed agitation granulator, mixed, wet granulated while adding water, fluidized bed dried after wet sizing, then dry sized Granules were obtained.
- Example 4 In the composition of Example 4, slight aggregation (aggregation that easily disintegrates as the bottle is inverted) was confirmed, but aggregation was completely suppressed by addition of light caustic anhydride.
- a pharmaceutical composition was prepared on a 25 kg scale with the composition ratio shown below.
- component I is charged into a high-speed agitation granulator as powder and mixed, then wet granulation is performed while adding bound water by spraying.After wet granulation, fluidized bed drying is performed, followed by dry sizing. A granulated product was produced. Ingredient II was added to this granulated product and mixed in a V-type mixer. The results are shown in Table 7.
- Equilibrium moisture content (25 ° C, relative humidity 70%) is 0.1%, the amount of gno-lease contained as impurities f is 0.001%, the amount of mannose f is 0.001 ⁇ / ⁇ .
- Equilibrium moisture content 25 ° C, relative humidity 70% is 0.0%.
- Amount is ND
- mannose amount is ND (ND: below detection limit).
- the present invention provides a pharmaceutical composition containing oseltamivir phosphate with improved storage stability, in particular, reduced coloration due to temperature and humidity in the storage environment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007800061380A CN101389323B (zh) | 2006-02-20 | 2007-02-20 | 含有磷酸奥塞米韦的药物组合物 |
US12/161,336 US9012499B2 (en) | 2006-02-20 | 2007-02-20 | Pharmaceutical composition comprising oseltamivir phosphate |
BRPI0708108-1A BRPI0708108B1 (pt) | 2006-02-20 | 2007-02-20 | Composição farmacêutica compreendendo fosfato de oseltamivir |
EP07714584.5A EP1987825B1 (en) | 2006-02-20 | 2007-02-20 | Pharmaceutical composition comprising oseltamivir phosphate |
AU2007218733A AU2007218733B2 (en) | 2006-02-20 | 2007-02-20 | Pharmaceutical composition comprising oseltamivir phosphate |
JP2008501722A JP5255429B2 (ja) | 2006-02-20 | 2007-02-20 | リン酸オセルタミビル含有医薬組成物 |
CA2642952A CA2642952C (en) | 2006-02-20 | 2007-02-20 | Pharmaceutical composition comprising oseltamivir phosphate |
IL193372A IL193372A (en) | 2006-02-20 | 2008-08-11 | Pharmaceutical preparation containing osmaltavir phosphate |
NO20083979A NO342112B1 (no) | 2006-02-20 | 2008-09-18 | Farmasøytisk sammensetning omfattende oseltamivirfosfat og anvendelse derav |
HK09106397.7A HK1126971A1 (en) | 2006-02-20 | 2009-07-15 | Pharmaceutical composition comprising oseltamivir phosphate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006042178 | 2006-02-20 | ||
JP2006-042178 | 2006-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007097325A1 true WO2007097325A1 (ja) | 2007-08-30 |
Family
ID=38437365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/053081 WO2007097325A1 (ja) | 2006-02-20 | 2007-02-20 | リン酸オセルタミビル含有医薬組成物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9012499B2 (ja) |
EP (1) | EP1987825B1 (ja) |
JP (1) | JP5255429B2 (ja) |
KR (1) | KR20080097468A (ja) |
CN (1) | CN101389323B (ja) |
AU (1) | AU2007218733B2 (ja) |
BR (1) | BRPI0708108B1 (ja) |
CA (1) | CA2642952C (ja) |
HK (1) | HK1126971A1 (ja) |
IL (1) | IL193372A (ja) |
NO (1) | NO342112B1 (ja) |
RU (1) | RU2008137613A (ja) |
SG (1) | SG183583A1 (ja) |
WO (1) | WO2007097325A1 (ja) |
ZA (1) | ZA200806356B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532390A (ja) * | 2006-04-04 | 2009-09-10 | インスティチュート オブ ファーマコロジー アンド トクシコロジー アカデミー オブ ミリタリー メディカル サイエンス、 ピー.エル.エー.チャイナ | リン酸オセルタミビル顆粒剤及びその調製方法 |
JP2011195557A (ja) * | 2010-02-24 | 2011-10-06 | Kyorin Pharmaceutical Co Ltd | 糖アルコールの選択方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101421330B1 (ko) * | 2008-12-17 | 2014-07-18 | 사토 세이야쿠 가부시키가이샤 | 붕괴정 |
WO2010143207A1 (en) | 2009-06-11 | 2010-12-16 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
CN102166206B (zh) * | 2011-02-12 | 2012-10-10 | 李春娟 | 液体的磷酸奥司他韦组合物 |
RU2633085C2 (ru) * | 2014-05-20 | 2017-10-11 | Российская Федерация, от имени которой выступает Федеральное государственное казенное учреждение "Войсковая часть 68240" | Противовирусное лекарственное средство в виде капсул и способ его получения |
KR20160002177A (ko) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | 오셀타미비어 유리염기를 포함하는 약학 조성물 |
WO2016052945A1 (en) * | 2014-09-30 | 2016-04-07 | Hanmi Pharm. Co., Ltd. | Granules containing oseltamivir, capsules comprising the granules, and method of preparing the capsules |
US20170258749A1 (en) | 2014-12-01 | 2017-09-14 | Lupin Atlantis Holdings Sa | Oseltamivir Compositions |
KR20160117070A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 오셀타미비어 함유 경구용 고형제제 및 그 제조방법 |
KR101953294B1 (ko) | 2018-04-12 | 2019-03-04 | 한미약품 주식회사 | 오셀타미비어 함유 경구용 고형제제 및 그 제조방법 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63156719A (ja) * | 1986-12-19 | 1988-06-29 | Kyorin Pharmaceut Co Ltd | シロツプ剤 |
JPH0827033A (ja) * | 1994-07-14 | 1996-01-30 | Nikken Chem Co Ltd | エリスリトール含有固形剤 |
WO1996026933A1 (en) | 1995-02-27 | 1996-09-06 | Gilead Sciences, Inc. | Novel selective inhibitors of viral or bacterial neuraminidases |
JPH1036291A (ja) * | 1996-04-16 | 1998-02-10 | Takeda Chem Ind Ltd | D−マンニトールおよびその製造法 |
WO1998007685A1 (en) | 1996-08-23 | 1998-02-26 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
JPH11310539A (ja) * | 1998-02-26 | 1999-11-09 | Banyu Pharmaceut Co Ltd | 口腔内崩壊型組成物及びその製造方法 |
JP2000505801A (ja) * | 1996-02-09 | 2000-05-16 | クアドラント・ホールディングズ・ケンブリッジ・リミテッド | トレハロースを含む固形製剤 |
US20040062801A1 (en) * | 2001-07-17 | 2004-04-01 | Joaquina Faour | Drug delivery device containing neuraminidase inhibitor and an H1 antagonist |
WO2007043538A1 (ja) * | 2005-10-05 | 2007-04-19 | Kyoto Pharmaceutical Industries, Ltd. | 経口用組成物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4292451A (en) * | 1978-03-30 | 1981-09-29 | Ici Americas Inc. | High mannitol process (alkaline hydrogenation in presence of alkali metal carbonate) |
JPH0723304B2 (ja) | 1988-04-19 | 1995-03-15 | 三菱化学株式会社 | 薬剤成分固定化組成物 |
JP4165878B2 (ja) | 1993-06-03 | 2008-10-15 | 株式会社林原生物化学研究所 | トレハロース遊離酵素とその製造方法並びに用途 |
BR9708672A (pt) | 1996-04-16 | 1999-08-03 | Bayer Ag | D-manitol e sua preparação |
JPH1135486A (ja) | 1997-07-23 | 1999-02-09 | Lion Corp | 薬用固形製剤 |
JP4367723B2 (ja) | 1997-08-25 | 2009-11-18 | 大正製薬株式会社 | 水難溶性成分を配合した固形剤 |
WO1999043306A1 (en) | 1998-02-26 | 1999-09-02 | Banyu Pharmaceutical Co., Ltd. | An orally disintegrating composition and its manufacturing method |
US20040202714A1 (en) * | 1999-10-12 | 2004-10-14 | Daiichi Suntory Pharma Co., Ltd. | Oral pharmaceutical composition |
HU229550B1 (en) | 2000-06-27 | 2014-01-28 | Hoffmann La Roche | Method for preparing compositions |
CN1820744B (zh) * | 2006-04-04 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 磷酸奥司他韦颗粒剂及其制备方法 |
EP2101738A2 (en) * | 2006-12-21 | 2009-09-23 | Mallinckrodt Inc. | Composition of and method for preparing orally disintegrating tablets |
-
2007
- 2007-02-20 AU AU2007218733A patent/AU2007218733B2/en active Active
- 2007-02-20 CA CA2642952A patent/CA2642952C/en active Active
- 2007-02-20 EP EP07714584.5A patent/EP1987825B1/en active Active
- 2007-02-20 SG SG2011011020A patent/SG183583A1/en unknown
- 2007-02-20 US US12/161,336 patent/US9012499B2/en active Active
- 2007-02-20 JP JP2008501722A patent/JP5255429B2/ja active Active
- 2007-02-20 CN CN2007800061380A patent/CN101389323B/zh active Active
- 2007-02-20 KR KR1020087022760A patent/KR20080097468A/ko active Application Filing
- 2007-02-20 WO PCT/JP2007/053081 patent/WO2007097325A1/ja active Application Filing
- 2007-02-20 RU RU2008137613/15A patent/RU2008137613A/ru unknown
- 2007-02-20 ZA ZA200806356A patent/ZA200806356B/xx unknown
- 2007-02-20 BR BRPI0708108-1A patent/BRPI0708108B1/pt active IP Right Grant
-
2008
- 2008-08-11 IL IL193372A patent/IL193372A/en active IP Right Grant
- 2008-09-18 NO NO20083979A patent/NO342112B1/no unknown
-
2009
- 2009-07-15 HK HK09106397.7A patent/HK1126971A1/xx unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63156719A (ja) * | 1986-12-19 | 1988-06-29 | Kyorin Pharmaceut Co Ltd | シロツプ剤 |
JPH0827033A (ja) * | 1994-07-14 | 1996-01-30 | Nikken Chem Co Ltd | エリスリトール含有固形剤 |
WO1996026933A1 (en) | 1995-02-27 | 1996-09-06 | Gilead Sciences, Inc. | Novel selective inhibitors of viral or bacterial neuraminidases |
US5952375A (en) * | 1995-02-27 | 1999-09-14 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
JP2000505801A (ja) * | 1996-02-09 | 2000-05-16 | クアドラント・ホールディングズ・ケンブリッジ・リミテッド | トレハロースを含む固形製剤 |
JPH1036291A (ja) * | 1996-04-16 | 1998-02-10 | Takeda Chem Ind Ltd | D−マンニトールおよびその製造法 |
WO1998007685A1 (en) | 1996-08-23 | 1998-02-26 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
JPH11310539A (ja) * | 1998-02-26 | 1999-11-09 | Banyu Pharmaceut Co Ltd | 口腔内崩壊型組成物及びその製造方法 |
US20040062801A1 (en) * | 2001-07-17 | 2004-04-01 | Joaquina Faour | Drug delivery device containing neuraminidase inhibitor and an H1 antagonist |
WO2007043538A1 (ja) * | 2005-10-05 | 2007-04-19 | Kyoto Pharmaceutical Industries, Ltd. | 経口用組成物 |
Non-Patent Citations (4)
Title |
---|
CHUUGAI SEIYAKU: "Rinshoi no tameno Shinyaku no Chishiki 2003 Ko Virus Yaku Ko Influenza Virus Yaku Rin San Oseltamivir Phosphate TAMIFLU dry Syrup", CLINICS & DRUG THERAPY, vol. 22, no. 4, 2003, pages 387, XP003017204 * |
GRAUL A. ET AL.: "Oseltamivir phosphate: anti-influenza, neuraminidase (sialidase) inhibitor", DRUGS OF THE FUTURE, vol. 24, no. 11, 1999, pages 1189 - 1202, XP003017205 * |
HIRAIWA S.: "TAMIFLU Dry Syrup no Fukuyosei ni okeru Tenkabutsu no eikyo", ANNUAL MEETING OF JAPANSE SOCIETY OF PHARMACEUTICAL HEALTH CARE AND SCIENCES KOEN YOSHISHU, vol. 14TH, 2004, pages 338, XP003017206 * |
See also references of EP1987825A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532390A (ja) * | 2006-04-04 | 2009-09-10 | インスティチュート オブ ファーマコロジー アンド トクシコロジー アカデミー オブ ミリタリー メディカル サイエンス、 ピー.エル.エー.チャイナ | リン酸オセルタミビル顆粒剤及びその調製方法 |
US9034382B2 (en) | 2006-04-04 | 2015-05-19 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Oseltamivir phosphate granule and preparation method thereof |
JP2011195557A (ja) * | 2010-02-24 | 2011-10-06 | Kyorin Pharmaceutical Co Ltd | 糖アルコールの選択方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2007218733B2 (en) | 2012-11-15 |
EP1987825A4 (en) | 2012-10-17 |
IL193372A0 (en) | 2009-09-22 |
SG183583A1 (en) | 2012-09-27 |
JPWO2007097325A1 (ja) | 2009-07-16 |
CA2642952C (en) | 2014-09-02 |
US9012499B2 (en) | 2015-04-21 |
CN101389323A (zh) | 2009-03-18 |
EP1987825B1 (en) | 2018-09-05 |
BRPI0708108A2 (pt) | 2011-05-17 |
KR20080097468A (ko) | 2008-11-05 |
RU2008137613A (ru) | 2010-03-27 |
IL193372A (en) | 2015-09-24 |
NO20083979L (no) | 2008-11-11 |
EP1987825A1 (en) | 2008-11-05 |
CN101389323B (zh) | 2013-08-21 |
US20100222427A1 (en) | 2010-09-02 |
BRPI0708108B1 (pt) | 2021-12-14 |
HK1126971A1 (en) | 2009-09-18 |
AU2007218733A1 (en) | 2007-08-30 |
CA2642952A1 (en) | 2007-08-30 |
ZA200806356B (en) | 2009-11-25 |
NO342112B1 (no) | 2018-03-26 |
JP5255429B2 (ja) | 2013-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007097325A1 (ja) | リン酸オセルタミビル含有医薬組成物 | |
EP2413913B1 (en) | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same | |
US8097651B2 (en) | Diclofenac formulations and methods of use | |
RU2600831C2 (ru) | Перорально вводимая фармацевтическая композиция | |
CA2681587A1 (en) | Stabilised pharmaceutical composition containing pregabaline | |
US20100016378A1 (en) | Method of preventing dihydropyridine compound from degradation | |
JP2022082819A (ja) | 医薬組成物 | |
WO2015099139A1 (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
PL236001B1 (pl) | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję | |
JP4890657B1 (ja) | リマプロストとβ−シクロデキストリンを含有する錠剤 | |
KR20120130761A (ko) | 라미프릴 및 암로디핀 베실레이트의 고형 약제학적 제형, 및 이의 제조 | |
JP2010111630A (ja) | アズレンスルホン酸塩含有粒子及びその製造方法、ならびにこれを含む医薬製剤 | |
US20130035344A1 (en) | Pharmaceutical composition for oral administration | |
JP2015212259A (ja) | ロスバスタチンまたはその塩の安定化製剤 | |
JP2017132718A (ja) | トピラマートを含む固形製剤 | |
JP2011153119A (ja) | バンコマイシンまたはその塩を含有する錠剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008501722 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12161336 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007218733 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501706 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007714584 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/010106 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 193372 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2007218733 Country of ref document: AU Date of ref document: 20070220 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2642952 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780006138.0 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4966/CHENP/2008 Country of ref document: IN Ref document number: 1020087022760 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2008137613 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0708108 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080820 |